Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16100697 | 1.00 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL32664869 | 1.00 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL16100700 | 1.00 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL30959635 | 1.00 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL31688547 | 0.93 | MDM2 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL26008959 | 0.92 | MDM4 (0.50) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL31688964 | 0.91 | MDM4 (0.45) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL19410224 | 0.91 | MDM4 (0.46) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL31189249 | 0.91 | MDM4 (0.46) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL31688695 | 0.90 | MDM2 (0.48) | MDM4TP53MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4441069-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4419540-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4314012-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023069994-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022204412-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-29 | — | — | WO | disclosed |